# chronic obstructive pulmonary disease (COPD) - claude-opus-4-8

- Benchmark system: raw
- Repeat: 1
- Task type: DISEASE-STATE
- Tissue / sample source: lung tissue
- Comparison or endpoint: COPD versus normal control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Anthropic / claude-opus-4-8
- Message SHA-256: 75cb1462dc859d10e673df1637d9bfb35fbfd41f53bda923e17881eee80cc2ef
- Response HTTP status: 200
- Prompt tokens: 
- Completion tokens: 
- Reasoning tokens: 
- Total tokens: 
- API requests reported: 
- Elapsed seconds: 121.855
- Final benchmark system: raw; file rank 1/5; original repeat 1; model vendor: Anthropic

---
# Multidimensional Interpretation of COPD Transcriptomic Data

## 1. Overall Biological Interpretation

The transcriptomic profile reveals a predominantly regulatory and structural remodeling landscape in COPD lung tissue, with the majority of differentially expressed genes being non-coding RNAs, antisense transcripts, and long non-coding RNAs (lncRNAs). This pattern suggests **epigenetic and post-transcriptional dysregulation** as a central feature of COPD pathobiology rather than dramatic shifts in core metabolic or structural protein-coding genes.

The upregulated genes indicate activation of **extracellular matrix remodeling** (GREM1, FGG), **immune/inflammatory signaling** (DEFB1, PTPRCAP), and **lipid metabolism alterations** (LDLR-AS1). The downregulated genes, though fewer, include ribosomal and translational machinery components (UQCRBP1, RPL23AP32, NACA2), suggesting **impaired protein synthesis capacity** or altered cellular composition favoring cells with lower translational activity.

Notably, the effect sizes are modest (most log2FC between 0.7–2.0), and many top hits are poorly characterized non-coding elements, limiting immediate mechanistic interpretation but highlighting potential novel regulatory axes in COPD.

---

## 2. Core Biological Programs

### Program 1: **Non-coding RNA Regulatory Networks**
- **Direction:** Predominantly upregulated
- **Major supporting genes:** CELF2-AS1 (log2FC=2.06), RN7SK (1.77), PTCSC1 (1.62), MIR132 (1.65), IRAIN (1.02), multiple antisense transcripts (SNX29-AS3, LRP1-AS, PRKCH-AS2)
- **Pathway association:** No single standardized pathway; represents trans-regulatory networks
- **Interpretation:** The overwhelming representation of lncRNAs and antisense RNAs (>30% of significant hits) suggests widespread transcriptional and post-transcriptional regulatory reprogramming. CELF2-AS1 regulates CELF2, an RNA-binding protein involved in alternative splicing. MIR132 is a well-characterized miRNA in neuronal and inflammatory contexts. RN7SK regulates RNA polymerase II transcriptional pausing. These elements collectively indicate **coordinated epigenetic silencing, splicing alterations, and transcriptional control** that may orchestrate multiple downstream COPD phenotypes.
- **Evidence strength:** Moderate. The statistical significance is robust, but functional validation of most individual lncRNAs in COPD is lacking. The coordinated upregulation suggests biological importance, but specificity to COPD versus general lung stress response is unclear.
- **Limitations:** Most lncRNAs lack functional characterization. Direction of effect (pathogenic vs. compensatory) cannot be determined from expression alone. Tissue composition changes (e.g., fibroblast enrichment) could drive some lncRNA signals.

---

### Program 2: **Extracellular Matrix Remodeling and Fibrotic Signaling**
- **Direction:** Upregulated
- **Major supporting genes:** GREM1 (log2FC=1.65, FDR=0.0072), FGG (1.76, FDR=0.0053), TGFB2-AS1 (1.04), MACF1 (1.56)
- **Pathway association:** GO:0030198 Extracellular matrix organization; Reactome: Extracellular matrix organization
- **Interpretation:** GREM1 (Gremlin 1) is a BMP antagonist that promotes TGF-β-driven fibrosis and has been genetically linked to COPD and pulmonary fibrosis. FGG (fibrinogen gamma chain) indicates coagulation cascade activation and provisional matrix deposition, common in tissue remodeling. TGFB2-AS1 is an antisense regulator of TGF-β2. MACF1 is a cytoskeletal crosslinker involved in epithelial integrity and wound healing. Together, these genes indicate **active tissue remodeling with pro-fibrotic signaling**, a hallmark of advanced COPD and emphysema repair attempts.
- **Evidence strength:** Strong. GREM1 has genetic (GWAS), expression, and functional evidence in COPD. FGG elevation is consistent with local coagulation and inflammation. Multiple independent genes converge on ECM remodeling.
- **Limitations:** Cannot distinguish adaptive remodeling from maladaptive fibrosis. Disease stage and emphysema severity may strongly influence this signal. GREM1 association with COPD is well-established, so its presence here confirms rather than discovers biology.

---

### Program 3: **Innate Immune Defense and Antimicrobial Response**
- **Direction:** Upregulated
- **Major supporting genes:** DEFB1 (log2FC=1.40, FDR=0.0074), IGKV1-8 (1.84, FDR=0.00086), NCR3LG1 (0.95, FDR=0.0045), SERPINB9-AS1 (1.12)
- **Pathway association:** GO:0006952 Defense response; GO:0002227 Innate immune response in mucosa
- **Interpretation:** DEFB1 (defensin beta 1) is an antimicrobial peptide critical for airway mucosal defense. Its upregulation suggests **chronic microbial stimulation or compensatory antimicrobial response**, consistent with bacterial colonization common in COPD. IGKV1-8 (immunoglobulin kappa variable) indicates B-cell or plasma cell presence, reflecting adaptive immune infiltration or tertiary lymphoid structures in diseased lung. NCR3LG1 is a ligand for the natural killer cell receptor NKp30, suggesting NK cell involvement. This program reflects **sustained innate and adaptive immune activation**, likely driven by chronic infection, microbiome alterations, or persistent inflammatory stimuli.
- **Evidence strength:** Moderate to strong. Individual genes are functionally relevant, but the sparse representation (3 core genes) limits network-level confidence. Tissue composition (immune cell infiltration) is a major confounder.
- **Limitations:** Immune gene expression may primarily reflect increased immune cell content rather than altered per-cell expression. DEFB1 upregulation could be compensatory or insufficient (i.e., COPD patients still experience infections despite defensin upregulation). No direct evidence of which pathogens or danger signals are driving this response.

---

### Program 4: **Lipid Metabolism and Cholesterol Homeostasis Dysregulation**
- **Direction:** Mixed (both up and down components)
- **Major supporting genes:** LDLR-AS1 (log2FC=1.03, FDR=0.0044), POMK (1.06, FDR=0.0012), BCAT1-AS1 (1.05), MGAM (1.49, FDR=0.0011)
- **Pathway association:** GO:0008203 Cholesterol metabolic process; Reactome: Cholesterol biosynthesis
- **Interpretation:** LDLR-AS1 is an antisense regulator of the LDL receptor, suggesting **altered lipid uptake or cholesterol trafficking**. POMK (protein O-mannose kinase) is involved in glycosylation but has been linked to lipid droplet regulation. MGAM (maltase-glucoamylase) is a carbohydrate-digesting enzyme, but its expression in lung may relate to metabolic reprogramming. The modest effect sizes and indirect evidence (mostly via lncRNAs) suggest **subtle metabolic rewiring** rather than overt metabolic dysfunction, potentially reflecting altered lipid utilization in stressed or remodeling cells, or changes in surfactant metabolism in alveolar cells.
- **Evidence strength:** Weak to moderate. Evidence is indirect (lncRNAs, limited core metabolic genes). Lipid metabolism alterations in COPD are reported but not universally accepted as central mechanisms.
- **Limitations:** Few direct lipid metabolism genes are present. Effect sizes are modest. The biological relevance of LDLR-AS1 upregulation to COPD pathogenesis is unclear. Surfactant alterations, if present, would be important, but no surfactant protein genes appear in this list.

---

### Program 5: **Translation and Protein Synthesis Attenuation**
- **Direction:** Downregulated
- **Major supporting genes:** UQCRBP1 (log2FC=-1.20, FDR=3.1×10⁻⁶), RPL23AP32 (-1.66, FDR=0.00014), NACA2 (-1.15, FDR=0.00040)
- **Pathway association:** GO:0006412 Translation; Reactome: Translation
- **Interpretation:** UQCRBP1 is a mitochondrial ribosomal protein involved in oxidative phosphorylation. RPL23AP32 is a ribosomal protein pseudogene, potentially reflecting reduced ribosomal activity or ribosomal stress. NACA2 (nascent polypeptide-associated complex alpha subunit 2) is a ribosome-associated chaperone. The coordinated downregulation suggests **reduced translational capacity or a shift in cellular composition toward cell types with lower protein synthesis rates** (e.g., senescent cells, quiescent fibroblasts, or loss of metabolically active epithelial cells). This could reflect cellular stress, bioenergetic failure, or selective loss of type II pneumocytes and other active epithelial populations in emphysema.
- **Evidence strength:** Moderate. The genes are biologically coherent, but limited in number. This could reflect true cellular dysfunction or compositional changes.
- **Limitations:** Only 3 clearly interpretable genes. Cannot distinguish reduced per-cell translation from altered cell-type proportions. Ribosomal pseudogenes may have non-canonical functions. No direct measures of translation rates or ribosomal profiling are available.

---

## 3. Key Genes and Interaction Modules

### Gene 1: **GREM1** (Gremlin 1)
- **Direction:** Upregulated (log2FC=1.65, FDR=0.0072)
- **Role:** Central node in ECM remodeling program. GREM1 antagonizes BMP signaling, promoting TGF-β-driven fibrosis. Genetic variants near GREM1 are among the strongest GWAS hits for COPD and pulmonary fibrosis.
- **Interactions:** GREM1 directly binds BMPs (BMP2, BMP4, BMP7), preventing BMP receptor activation. Pathway co-membership with TGF-β signaling components (TGFB2-AS1 present in dataset). No direct physical interaction with other genes in this dataset.
- **Priority:** High. Established disease-association, druggable pathway, and clear mechanistic role.

---

### Gene 2: **CELF2-AS1** (CELF2 antisense RNA 1)
- **Direction:** Upregulated (log2FC=2.06, top effect size, FDR=1.1×10⁻⁸)
- **Role:** Antisense regulator of CELF2, an RNA-binding protein that controls alternative splicing and mRNA stability. CELF2 targets are enriched in neuronal and muscle transcripts, but also regulate inflammatory and fibrotic gene expression.
- **Interactions:** Regulatory interaction with CELF2 (not directly measured here). CELF2 targets hundreds of mRNAs, so CELF2-AS1 upregulation could have widespread downstream effects. No direct physical interaction evidence with other dataset genes.
- **Priority:** Medium. Large effect size and potential for broad regulatory impact, but functional validation in COPD lung is absent.

---

### Gene 3: **MIR132** (MicroRNA 132)
- **Direction:** Upregulated (log2FC=1.65, FDR=2.4×10⁻⁷)
- **Role:** MicroRNA involved in immune regulation, angiogenesis, and neuronal function. Targets include SIRT1, FOXO3, and acetylcholinesterase. In lung, MIR132 upregulation has been linked to inflammation and fibrosis in some models.
- **Interactions:** Regulatory interactions (via mRNA targeting) with hundreds of transcripts. Potential pathway co-membership with inflammatory and ECM genes. No direct physical interaction.
- **Priority:** Medium-high. Well-characterized miRNA with druggable potential (antagomirs), but COPD-specific functional validation needed.

---

### Gene 4: **DEFB1** (Defensin Beta 1)
- **Direction:** Upregulated (log2FC=1.40, FDR=0.0074)
- **Role:** Antimicrobial peptide. Reflects innate immune activation and chronic microbial exposure or colonization.
- **Interactions:** Secreted peptide; no direct protein-protein interactions within this dataset. Pathway co-membership with other innate immune genes (IGKV1-8, NCR3LG1).
- **Priority:** Medium. Biomarker potential for infection/colonization status. Unclear if upregulation is protective or insufficient.

---

### Gene 5: **FGG** (Fibrinogen Gamma Chain)
- **Direction:** Upregulated (log2FC=1.76, FDR=0.0053)
- **Role:** Component of fibrinogen, involved in coagulation and provisional ECM. Elevated fibrinogen is a biomarker of systemic inflammation in COPD and predicts exacerbations.
- **Interactions:** Physical interaction with FGA and FGB to form fibrinogen hexamer (not measured here). Pathway co-membership with ECM and coagulation cascade genes.
- **Priority:** Medium. Established biomarker, but unclear if local lung expression drives disease or reflects systemic inflammation.

---

### Gene 6: **MACF1** (Microtubule-Actin Crosslinking Factor 1)
- **Direction:** Upregulated (log2FC=1.56, FDR=4.0×10⁻⁷)
- **Role:** Giant cytoskeletal protein linking microtubules and actin. Involved in cell migration, wound healing, and epithelial integrity. Mutations cause skin blistering and neurological disorders.
- **Interactions:** Physical interaction with actin, microtubules, and plakin family proteins. Potential role in coordinating mechanical stress responses in remodeling lung tissue.
- **Priority:** Medium. Large effect size and early statistical rank, but limited COPD-specific evidence. Could reflect active tissue repair or maladaptive remodeling.

---

### Gene 7: **UQCRBP1** (Ubiquinol-Cytochrome C Reductase Binding Protein 1)
- **Direction:** Downregulated (log2FC=-1.20, top downregulated gene, FDR=3.1×10⁻⁶)
- **Role:** Mitochondrial ribosomal protein involved in oxidative phosphorylation. Downregulation suggests **mitochondrial dysfunction or bioenergetic stress**, a recognized feature of COPD epithelium.
- **Interactions:** Pathway co-membership with other mitochondrial and ribosomal genes (RPL23AP32, NACA2). No direct physical interactions within dataset.
- **Priority:** High. Mitochondrial dysfunction is a mechanistic hypothesis in COPD. This finding supports further investigation of bioenergetic failure.

---

### Gene 8: **LDLR-AS1** (LDL Receptor Antisense RNA 1)
- **Direction:** Upregulated (log2FC=1.03, FDR=0.0044)
- **Role:** Antisense regulator of LDLR, potentially modulating cholesterol uptake. Cardiovascular comorbidities are common in COPD, and lipid metabolism may influence lung inflammation and repair.
- **Interactions:** Regulatory interaction with LDLR (not measured). Indirect connection to cholesterol and lipid pathways.
- **Priority:** Low-medium. Intriguing but speculative. Lipid metabolism in COPD lung remains underexplored.

---

### Gene 9: **IGKV1-8** (Immunoglobulin Kappa Variable 1-8)
- **Direction:** Upregulated (log2FC=1.84, FDR=0.00086)
- **Role:** Immunoglobulin variable region gene. Reflects B-cell or plasma cell infiltration, consistent with tertiary lymphoid structures in advanced COPD.
- **Interactions:** Part of adaptive immune response; no direct interactions with other genes in dataset.
- **Priority:** Medium. Biomarker for immune infiltration. May identify COPD subgroups with prominent adaptive immunity.

---

### Gene 10: **RN7SK** (RNA Component of 7SK Nuclear Particle)
- **Direction:** Upregulated (log2FC=1.77, FDR=3.1×10⁻⁶)
- **Role:** Non-coding RNA that sequesters and inhibits the positive transcription elongation factor b (P-TEFb), regulating RNA polymerase II pausing and transcriptional elongation.
- **Interactions:** Physical interaction with HEXIM1 and CDK9 (P-TEFb components, not measured). Regulatory interaction affecting global transcription.
- **Priority:** Medium. Could be a master regulator of transcriptional stress response, but functional role in COPD lung is unknown.

---

## 4. Validation Priorities

### Priority 1: **GREM1 as a therapeutic target in COPD fibrosis**
- **Classification:** Therapeutic target
- **Rationale:** GREM1 has the strongest convergent evidence: GWAS signal, upregulation in diseased tissue, and clear mechanistic link to fibrosis. Anti-GREM1 or BMP-agonist therapies could reverse pro-fibrotic signaling.
- **Current evidence:** Genetic (GWAS), expression (this dataset, prior studies), pathway (TGF-β/BMP antagonism).
- **External evidence:** GREM1 overexpression in mouse lung causes fibrosis. Genetic variants near GREM1 (rs1036429) are robustly associated with COPD in multiple cohorts.
- **Next steps:** Functional validation in human lung organoids or precision-cut lung slices. Test BMP pathway activation or GREM1 neutralization in COPD models.
- **Conclusion level:** **Supported hypothesis.** GREM1 is a leading candidate, but causality and druggability in human COPD require validation.

---

### Priority 2: **Mitochondrial dysfunction and bioenergetic failure**
- **Classification:** Mechanistic hypothesis
- **Rationale:** Downregulation of UQCRBP1 and other translational machinery suggests impaired oxidative phosphorylation and protein synthesis. Mitochondrial dysfunction is implicated in COPD epithelial senescence and apoptosis.
- **Current evidence:** Expression (this dataset), pathway (mitochondrial ribosome, OXPHOS).
- **External evidence:** Prior studies show mitochondrial DNA damage, reduced mitochondrial biogenesis (PGC-1α downregulation), and increased ROS in COPD lung epithelial cells.
- **Next steps:** Measure mitochondrial function (oxygen consumption, ATP production) in COPD lung tissue or isolated cells. Assess mitochondrial morphology and quality control (mitophagy) markers.
- **Conclusion level:** **Supported hypothesis.** Converges with prior evidence, but limited gene number and potential confounding by cell composition require careful validation.

---

### Priority 3: **Non-coding RNA regulatory network as disease orchestrator**
- **Classification:** Mechanistic hypothesis / Network hypothesis
- **Rationale:** The dominant signal is lncRNAs and antisense transcripts, suggesting a coordinated regulatory layer controlling COPD pathobiology. If validated, these could be novel therapeutic or biomarker targets.
- **Current evidence:** Expression (this dataset, >30% of hits are non-coding).
- **External evidence:** Emerging evidence for lncRNA dysregulation in COPD (e.g., MALAT1, H19), but most lncRNAs in this dataset are uncharacterized.
- **Next steps:** Functional screening of top lncRNAs (CELF2-AS1, MIR132, RN7SK) in COPD-relevant cellular models (e.g., bronchial epithelial cells exposed to cigarette smoke). RNA interference or CRISPR-mediated knockout/activation studies.
- **Conclusion level:** **Exploratory hypothesis.** High biological plausibility but very limited functional validation. Many lncRNAs may be passenger signals.

---

### Priority 4: **Immune cell infiltration versus per-cell transcriptional changes**
- **Classification:** Confounding or composition check
- **Rationale:** Many immune-related genes (DEFB1, IGKV1-8, NCR3LG1) likely reflect increased immune cell content rather than altered per-cell expression. Deconvoluting cell-type contributions is critical to interpret causality.
- **Current evidence:** Expression data only; no cell-type resolution.
- **External evidence:** COPD lung has well-documented immune infiltration (macrophages, neutrophils, lymphocytes) and tertiary lymphoid structures.
- **Next steps:** Cell-type deconvolution using established methods (CIBERSORT, xCell, or single-cell reference datasets). Ideally, validate with spatial transcriptomics or single-cell RNA-seq from same or comparable samples.
- **Conclusion level:** **Critical methodological priority.** Without this, immune and ECM signals cannot be confidently attributed to altered cellular function versus altered tissue composition.

---

### Priority 5: **MIR132 as a druggable inflammatory regulator**
- **Classification:** Therapeutic target / Biomarker
- **Rationale:** MIR132 is upregulated with strong significance, has broad regulatory targets, and is druggable via antagomir technology. It regulates SIRT1 and FOXO3, which are implicated in aging and cellular stress responses relevant to COPD.
- **Current evidence:** Expression (this dataset).
- **External evidence:** MIR132 inhibition reduces lung inflammation in some models. Overexpression is linked to fibrosis and impaired autophagy in other contexts.
- **Next steps:** Test MIR132 antagomir in cigarette smoke or elastase models of COPD in mice. Measure MIR132 levels in patient plasma or sputum as a biomarker of disease activity or exacerbation.
- **Conclusion level:** **Exploratory hypothesis.** Druggability is an advantage, but COPD-specific functional evidence is lacking. Could represent compensatory or pathogenic activity.

---

## 5. Evidence Grounding

### Evidence Summary by Category:

**Direct evidence from input dataset:**
- All genes listed have robust statistical evidence (FDR < 0.01, most < 0.001).
- Effect directions are clear; effect sizes are modest (log2FC mostly 0.7–2.0).

**Pathway / ontology evidence:**
- ECM remodeling program: Supported by GO, Reactome, KEGG databases (GREM1, FGG, MACF1).
- Translation/ribosome program: Supported by GO Translation pathway (UQCRBP1, RPL23AP32, NACA2).
- Innate immunity: Supported by GO Defense response (DEFB1, NCR3LG1).

**Protein interaction or regulatory evidence:**
- GREM1-BMP interaction: Direct physical interaction (protein-protein), well-documented in multiple species.
- CELF2-AS1-CELF2: Regulatory interaction (antisense-target), supported by genomic position and some functional studies.
- MIR132: Regulatory interaction (miRNA-mRNA targeting), extensively validated for multiple targets (SIRT1, FOXO3, PTEN).
- Most lncRNAs: Indirect or putative interactions only.

**Disease-association evidence:**
- GREM1: Strong (GWAS, expression studies in COPD, functional studies in fibrosis models). **Independent evidence sources.**
- FGG: Moderate (systemic biomarker studies, some lung expression data). Evidence sources partially overlapping (systemic inflammation correlates with lung disease).
- DEFB1: Moderate (expression studies, functional relevance to infection). Evidence primarily expression-based; limited genetic or functional validation in COPD.
- Most lncRNAs: Weak or absent.

**Genetic evidence:**
- GREM1: Strong GWAS signal (rs1036429 and nearby variants) in multiple COPD cohorts.
- No other genes in this list have strong GWAS associations with COPD.

**Drug or therapeutic evidence:**
- GREM1: No approved drugs, but BMP agonists and GREM1 neutralizing antibodies are in preclinical development for fibrosis.
- MIR132: Antagomirs are in development; no COPD trials.
- LDLR: Statins target cholesterol metabolism, widely used in cardiovascular comorbidities of COPD, but no evidence that LDLR modulation affects COPD lung pathology.

**Conflicting evidence:**
- DEFB1 upregulation: Could be protective (enhanced antimicrobial defense) or insufficient (patients still have infections), or a marker of chronic bacterial colonization. **Directional ambiguity.**
- Lipid metabolism signals (LDLR-AS1, POMK): Some studies suggest cholesterol efflux is protective in COPD (via ABCA1), while others link hypercholesterolemia to worse outcomes. **Pathway-level ambiguity.**

**Insufficient evidence:**
- Most lncRNAs (SNX29-AS3, PTCSC1, IRAIN, USP6NL-AS1, etc.): **Insufficient functional evidence** to assign biological roles in COPD. Annotations are sparse or absent.
- LOC genes (multiple): Uncharacterized or poorly annotated. **Cannot interpret without further investigation.**

---

## 6. Limitations and Alternative Explanations

### Limitation 1: **Tissue and cell-composition differences**
The most significant confounder. COPD lung tissue exhibits:
- Loss of alveolar epithelial cells (emphysema)
- Increased fibroblasts and myofibroblasts (remodeling)
- Immune cell infiltration (macrophages, neutrophils, lymphocytes)
- Vascular remodeling

**Impact:** Immune gene upregulation (DEFB1, IGKV1-8, NCR3LG1) likely reflects increased immune cell content. Ribosomal gene downregulation (UQCRBP1, RPL23AP32) may reflect loss of metabolically active epithelial cells rather than per-cell translational shutdown. ECM gene upregulation (GREM1, FGG) could reflect fibroblast expansion rather than altered per-cell fibrotic signaling.

**Mitigation:** Cell-type deconvolution, validation in isolated cell populations, or spatial transcriptomics to assign signals to specific cell types.

---

### Limitation 2: **Disease severity and stage heterogeneity**
COPD is a heterogeneous disease. Samples may include:
- Mild to severe airflow obstruction
- Emphysema-dominant vs. chronic bronchitis-dominant phenotypes
- Active smokers vs. ex-smokers
- Exacerbation-prone vs. stable patients

**Impact:** Signals like DEFB1 upregulation may be driven by a subset with chronic bacterial colonization. ECM remodeling may be more prominent in advanced disease. Severity-related heterogeneity could obscure or amplify certain signals.

**Mitigation:** Stratified analysis by disease severity (GOLD stage), smoking status, or exacerbation history. Correlation of gene expression with clinical or physiological parameters (FEV1, emphysema score).

---

### Limitation 3: **Smoking exposur
